Clinical Trials Logo

Procalcitonin clinical trials

View clinical trials related to Procalcitonin.

Filter by:

NCT ID: NCT01227109 Not yet recruiting - Cancer Clinical Trials

Procalcitonin as a Marker of Infection in Cancer Patients

Start date: February 2011
Phase: N/A
Study type: Observational

Infections pose a serious threat to cancer patients in chemotherapy. Prompt diagnosis and treatment is of paramount importance as infections may be life-threatening in immune-compromised individuals. Traditionally, the C-reactive protein (CRP) has been used as a marker of infection. However, the CRP is also often elevated in cancer patients and as a marker CRP may be unreliable in cancer patients. Other markers for infection includes procalcitonin which has been showed to be of some value for the diagnose of bacterial infections. This study examines procalcitonin as a potential marker of bacterial infection in cancer patients.

NCT ID: NCT01182688 Completed - Clinical trials for Coronary Artery Bypass Grafting

Prospective Review of Procalcitonin After Cardiac Surgery

Start date: May 2009
Phase: N/A
Study type: Observational

This study is designed to demonstrate the value of Procalcitonin (PCT) in assisting the rapid diagnosis of post- operative infection that includes elevation of Procalcitonin above and beyond the changes seen with the acute and inflammatory response induced by cardio-pulmonary bypass. Procalcitonin is an innovative and highly specific biomarker for clinically relevant severe bacterial infections and sepsis. PCT supports early diagnosis and clinical decision making.This is a prospective single center study designed to assess the normal change in PCT levels following major surgery and the utilization of PCT regarding the diagnosis of infection and the response to treatment, following major cardiac surgery

NCT ID: NCT00692848 Completed - Bacteremia Clinical Trials

Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source

Start date: November 2006
Phase: N/A
Study type: Interventional

Serious bacterial infections are often difficult to detect in children with fever without source. Procalcitonin is a better blood marker of infection than White blood cell count and possibly than C-reactive protein. This could lead to a reduction in antibiotic prescription. Our objective is to evaluate the impact of Procalcitonin result on antibiotic prescription in children 1 to 36 month old with fever without source and our hypothesis is that it will lower the antibiotic prescription rate